GR3029491T3 - Use of leflunomid for the inhibition of interleukin 1 beta. - Google Patents

Use of leflunomid for the inhibition of interleukin 1 beta.

Info

Publication number
GR3029491T3
GR3029491T3 GR990400587T GR990400587T GR3029491T3 GR 3029491 T3 GR3029491 T3 GR 3029491T3 GR 990400587 T GR990400587 T GR 990400587T GR 990400587 T GR990400587 T GR 990400587T GR 3029491 T3 GR3029491 T3 GR 3029491T3
Authority
GR
Greece
Prior art keywords
interleukin
beta
leflunomid
inhibition
methylisoxazole
Prior art date
Application number
GR990400587T
Other languages
Greek (el)
English (en)
Inventor
Klaus Ulrich Dr Weithmann
Robert Ryder Dr Bartlett
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of GR3029491T3 publication Critical patent/GR3029491T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GR990400587T 1993-01-08 1999-02-25 Use of leflunomid for the inhibition of interleukin 1 beta. GR3029491T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4300277 1993-01-08

Publications (1)

Publication Number Publication Date
GR3029491T3 true GR3029491T3 (en) 1999-05-28

Family

ID=6477853

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990400587T GR3029491T3 (en) 1993-01-08 1999-02-25 Use of leflunomid for the inhibition of interleukin 1 beta.

Country Status (8)

Country Link
US (1) US5556870A (enExample)
EP (1) EP0607775B1 (enExample)
JP (1) JPH06234635A (enExample)
AT (1) ATE174218T1 (enExample)
DE (1) DE59407413D1 (enExample)
DK (1) DK0607775T3 (enExample)
ES (1) ES2124800T3 (enExample)
GR (1) GR3029491T3 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
DE19711800A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
AU3080299A (en) * 1998-03-11 1999-09-27 Ohio State University Research Foundation, The Anti-viral uses of leflunomide products
US7691890B2 (en) 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
DE19847823A1 (de) 1998-10-16 2000-04-20 Aventis Pharma Gmbh Substituierte Thiadiazolsulfonamide
DE19860802A1 (de) * 1998-12-30 2000-10-26 Virgene Pharmaceuticals Ag Herstellung eines Mittels gegen Hepatitis B-, HI-, Paramyxo und Orthomyxo-Viren
US6589992B2 (en) 1999-11-30 2003-07-08 Parker Hughes Institute Inhibiting collagen-induced platelet aggregation
AU4508601A (en) * 1999-11-30 2001-06-18 Parker Hughes Institute Inhibitors of collagen-induced platelet aggregation
EP1257270B1 (en) 2000-02-15 2005-04-13 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
EP1473035A1 (en) * 2000-02-15 2004-11-03 Teva Pharmaceutical Industries Ltd. Leflunomide of high purity
NZ589307A (en) * 2008-04-29 2012-04-27 Pharnext Compositions comprising baclogen or terbinafine for treating alzheimer disease and related disorders through a modulation of angiogenesis
US10813917B2 (en) 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
LT2509619T (lt) * 2009-12-11 2021-04-12 Medregen, Llc Gydymo būdai, naudojant kamieninių ląstelių mobilizatorius ir imunosupresijos agentus
WO2012025217A1 (en) * 2010-08-24 2012-03-01 Algiax Pharmaceuticals Gmbh Novel use of leflunomide and malononitrilamides
EP3344243B1 (en) * 2015-09-01 2020-12-09 The Broad Institute, Inc. Compounds and methods useful for treating or preventing hematological cancers
WO2018096538A1 (en) * 2016-11-23 2018-05-31 Ramot At Tel-Aviv University Ltd. Methods and compositions for treating disorders associated with cortico-hippocampal hyperactivity
CN117442613A (zh) * 2023-06-07 2024-01-26 中国医学科学院医药生物技术研究所 一组来氟米特及其活性代谢物的制药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
AU649421B2 (en) * 1990-05-18 1994-05-26 Sanofi-Aventis Deutschland Gmbh Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
AU8337291A (en) * 1990-08-06 1992-03-02 Cetus Corporation Methods for the identification of cytokine convertase inhibitors
WO1992016226A1 (en) * 1991-03-19 1992-10-01 Smithkline Beecham Corporation Il-1 inhibitors
AU7629594A (en) * 1993-07-21 1995-02-20 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease

Also Published As

Publication number Publication date
US5556870A (en) 1996-09-17
DK0607775T3 (da) 1999-08-16
DE59407413D1 (de) 1999-01-21
EP0607775A2 (de) 1994-07-27
ATE174218T1 (de) 1998-12-15
EP0607775A3 (enExample) 1994-08-31
EP0607775B1 (de) 1998-12-09
JPH06234635A (ja) 1994-08-23
ES2124800T3 (es) 1999-02-16

Similar Documents

Publication Publication Date Title
EP0607775A3 (enExample)
KR100344712B1 (ko) 알러지성및염증성질환의치료에유용한화합물
GR3036347T3 (en) Compounds useful for treating allergic and inflammatory diseases.
EP0607776A3 (enExample)
HU9303218D0 (en) Application of atp-depended protease and its inhibitor for treatment of cachexy and amyotrophia
NZ237023A (en) 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions
AU3951389A (en) The use of alpha-amino boronicacid derivatives for the prophylaxis and treatment of virus diseases
NO902800L (no) Fremgangsmaate for fremstilling av 11beta-aryl-4-oestrener.
GR3029489T3 (en) Use of leflunomid for the inhibition of interleukin 8.
EP0328634A4 (en) Pharmaceutical compositions for the treatment of psoriasis
AU2806692A (en) Medicament for the treatment of anxiety
IT1271567B (it) Procedimento per l'ulteriore trattamento di salcicce
DE69214608D1 (de) Kristallmodifikation von 2-(3-Methylanilino)-3-Methyl-6-Diethylaminofluoran, Verfahren zur dessen Herstellung und Aufzeichnungsmaterial, welches diese Kristallmodifikation enthält
TW325997B (en) Pharmaceutical composition for preventing and treating retinal diseases
BR9301567A (pt) Aparelho para o tratamento magnético de combustível
IL104132A0 (en) Compositions for the treatment of mammalian diseases
GR3029492T3 (en) Use of leflunomid for the inhibition of interleukin 1 alpha.
IE792418L (en) Diazines.
LV10391A (lv) Alkilfosforskabes savienojumu izmantosana psoriazes tipa slimibu arstesanai
HU9402816D0 (en) Medicament for the treatment of airways inflammation and airways hyperresponsiveness
MY104318A (en) Novel thiopen compounds and their preparation
CA2145211A1 (en) The use of deoxyspergualin for preparing a pharmaceutical for treating hyperreactive inflammatory diseases
ZA961897B (en) 6,7-substituted-2-aminotetralines and use thereof
GB2279567B (en) Compositions for the treatment of inflammatory proliferative skin disease and their use
LV5179A3 (lv) Preparats "etoksidins" teju kunga un zarnu slimibu profilaksei un arstesanai